Back
Ares Management 10K Form
Buy
65
ARES
Ares Management
Last Price:
$157.92
Seasonality Move:
11.51%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
2023-11-06 | 10Q | ARES/Ares Management Quarterly |
2023-08-03 | 10Q | ARES/Ares Management Quarterly |
2023-05-08 | 10Q | ARES/Ares Management Quarterly |
2022-11-07 | 10Q | ARES/Ares Management Quarterly |
2022-08-05 | 10Q | ARES/Ares Management Quarterly |
2022-05-09 | 10Q | ARES/Ares Management Quarterly |
Receive ARES News And Ratings
See the #1 stock for the next 7 days that we like better than ARES
ARES Financial Statistics
Sales & Book Value
Annual Sales: | $3.9B |
---|---|
Cash Flow: | $798.3M |
Price / Cash Flow: | 11.17 |
Annual Sales: | $10.25 |
Price / Book: | 15.16 |
Profitability
EPS (TTM): | 2.03000 |
---|---|
Net Income (TTM): | $463.7M |
Gross Margin: | $2.2B |
Return on Equity: | 8.82% |
Return on Assets: | 1.89% |
Ares Management Earnings Forecast
Key Ares Management Financial Ratios
-
The Gross Profit Margin over the past 14 years for ARES is 55.42%.
-
The Selling, General & Administrative Expenses for ARES have been equal to 30.53% of Gross Profit Margin.
-
The Research & Development expenses have been 0.00% of Revenue.
-
The Interest Expense is 210.96% of Operating Income.
-
The Net Earning history of ARES is 11.94% of Total Revenues.
-
Per Share Earnings over the last 14 years have been positive in 5 years.
Ares Management Stock Price Chart
Industry, Sector and Symbol
Stock Exchange: | NYSE |
---|---|
Industry: | Capital Markets |
Sector: | Financials |
Current Symbol: | ARES |
CUSIP: | 03990B |
Website: | aresmgmt.com |
Debt
Debt-to-Equity Ratio: | 3.53 |
---|---|
Current Ratio: | 0.98 |
Quick Ratio: | 0.98 |
Price-to-Earnings
Trailing P/E Ratio: | 74.64 |
---|---|
Forward P/E Ratio: | 23.86 |
ARES Technical Analysis vs Fundamental Analysis
Buy
65
Ares Management (ARES)
is a Buy
Is Ares Management a Buy or a Sell?
-
Ares Management stock is rated a BuyThe current Ares Management [ARES] share price is $152.27. The Score for ARES is 65, which is 30% above its historic median score of 50, and infers lower risk than normal.